CONGRESS|#EHA2021|@RobertoMinaMD, European Myeloma Network presented results for FORTE trial. Carfilzomib-lenalidomide-dexamethasone induction/consolidation with ASCT (KRd_ASCT) had improved PFS. Effective KR maintenance in pts with 1 yr-MRD negative rates obtained #mmsm #myeloma pic.twitter.com/YOEdE8zS1w
— Multiple Myeloma Hub (@MM_Hub) June 14, 2021